USWM, LLC (dba US WorldMeds)

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Phase 21

Phase 11

By Therapeutic Area

top 1

Oncology

1100%

R&D Momentum

12/100

Pipeline Velocity

0/100

Trial Completion Rate

88/100

Pipeline Concentration

100/100

Pipeline Freshness

35/100

Activity

Key Events

Jun 1, 2025TrialA Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects

Dec 13, 2023FDAOrnidyl — IWILFIN

Feb 16, 2021TrialA Study Evaluating the Relative Bioavailability of Lofexidine Granules for Reconstitution Compared to LUCEMYRA (Lofexidine) Tablets and the Effect of Food on the Bioavailability of the Lofexidine Granules for Reconstitution

Dec 31, 2019TrialStudy to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Aug 2, 2019TrialRandomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

1 patent group across drugs · Source: FDA Orange Book

DrugExpires

OrnidylFeb 12, 2036

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Oncology

Liposarcoma

Letetresgene autoleucel

Multiple Myeloma

Letetresgene autoleucel

Non-Small Cell Lung Cancer

Letetresgene autoleucel

Synovial Sarcoma

Letetresgene autoleucel

Oncology

Liposarcoma

Letetresgene autoleucelPhase 2

Multiple Myeloma

Letetresgene autoleucelPhase 1

Non-Small Cell Lung Cancer

Letetresgene autoleucelPhase 1

Synovial Sarcoma

Letetresgene autoleucelPhase 2

Regulatory

Regulatory Timeline

19861 event

FDAOct 28

Corgard — CORGARD

Application NDA018063 (NDA)

19901 event

FDANov 28

Ornidyl — ORNIDYL

Application NDA019879 (NDA)

20001 event

FDAJul 27

Ornidyl — VANIQA

Application NDA021145 (NDA)

20231 event

FDADec 13

Ornidyl — IWILFIN

Application NDA215500 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)